SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: CPark5/2/2020 12:43:56 PM
1 Recommendation

Recommended By
Dietman

  Read Replies (2) of 63278
 
HR+/HER2- BC is shaping up to be the biggest catalyst/question mark in the minds of Wall St. analysts. I’ve heard that Trop-2 is expressed differently than in mTNBC, thus leading to questions about ASCENT trial read through to TROPICS-02.

Does anyone have knowledge about different types of Trop-2 over expression and how that might affect TROPICS-02? It’s estimated that success in this indication could be 2-4 times bigger opportunity for Trodelvy. This is the next big question.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News